Britannica Sources used in this answer

How can factor replacement therapy control bleeding in hemophilia?

Created from Britannica articles using AI. AI can make mistakes, so verify using Britannica articles.

blood disease Peripheral blood smear revealing histopathologic features indicative of a blast crisis in a case of chronic myelogenous leukemia (CML). Blast crisis occurs when one-fifth to one-third of the cells in the blood or bone marrow are immature blood cells, or blast cells. This phase of CML is characterized by fever, weakness, and an enlarged spleen.

Factor replacement therapy controls bleeding in hemophilia by directly replenishing the specific coagulation factors that are deficient in the patient's blood.12

In a healthy individual, coagulation is a sequential process involving 13 factors that interact to form a stable fibrin mesh, which arrests blood loss from injured vessels. Because hemophilia is caused by a hereditary deficiency of these essential proteins—specifically factor VIII in hemophilia A or factor IX in hemophilia B—the body cannot effectively complete the clotting cascade.32

Therapy involves the infusion of these missing proteins, which are derived from pooled human plasma, cryoprecipitate, or produced via recombinant DNA technology. By introducing the necessary clotting factors into the bloodstream, the therapy restores the body's ability to initiate the coagulation cascade, allowing for the formation of a resilient clot and the successful management of bleeding episodes.123